/
STTK
$5.97-$0.23 (-3.71%)live
Change$-14.03
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$622.3M
100M shares
52-week range
$1.70 – $8.33
64% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
775
Shattuck Labs, Inc. Common Stock
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
www.shattucklabs.com- Employees
- 40
- IPO / List date
- Oct 9, 2020
- HQ
- AUSTIN, TX
Held by traders on TradeandTell
No one on the platform currently holds STTK.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 604,500 | $3.9M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2016-12-06 | 1-for-800reverse |
| 2009-03-31 | 1-for-250reverse |
Recent trades on TradeandTell
No one on the platform has traded STTK yet.
